Oral Δ9-tetrahydrocannabinol improved refractory Gilles de la Tourette syndrome in an adolescent by increasing intracortical inhibition: A case report

Journal of Clinical Psychopharmacology

Volumn 30, Issue 2, 2010, Pages 190-192

  Hasan, Alkomiet ^a   Rothenberger, Aribert ^a   Münchau, Alexander ^b   Wobrock, Thomas ^a   Falkai, Peter ^a   Roessner, Veit ^c  

^a UNIVERSITY OF GÖTTINGEN   (Germany)

^b UNIVERSITY OF HAMBURG   (Germany)

^c DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

Author keywords

9 tetrahydrocannabinol; Attention deficit hyperactiviy disorder; Tourette syndrome; Transcranial magnetic stimulation

Indexed keywords

ARIPIPRAZOLE; ATOMOXETINE; CANNABIS; CLONAZEPAM; DRONABINOL; HALOPERIDOL; METHYLPHENIDATE; OLANZAPINE; RISPERIDONE; SEROTONIN UPTAKE INHIBITOR; SULPIRIDE; TIAPRIDE;

ADD ON THERAPY; ADOLESCENT; ARTICLE; ATTENTION DEFICIT DISORDER; AUTOMUTILATION; CANNABIS SMOKING; CASE REPORT; COMORBIDITY; DISEASE COURSE; DISEASE SEVERITY; DRUG BLOOD LEVEL; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG SUBSTITUTION; DRUG WITHDRAWAL; EUPHORIA; EVOKED MUSCLE RESPONSE; GILLES DE LA TOURETTE SYNDROME; HUMAN; MALE; MORNING DOSAGE; NEUROPHYSIOLOGY; PHYSICAL DISEASE; PRIORITY JOURNAL; PSYCHOSOCIAL CARE; PSYCHOSOCIAL DISORDER; QUALITY OF LIFE; SIDE EFFECT; SUICIDAL BEHAVIOR; SUICIDAL IDEATION; TRANSCRANIAL MAGNETIC STIMULATION; TREATMENT RESPONSE;

ADMINISTRATION, ORAL; ADOLESCENT; CEREBRAL CORTEX; HUMANS; MALE; NEURAL INHIBITION; TETRAHYDROCANNABINOL; TOURETTE SYNDROME; TRANSCRANIAL MAGNETIC STIMULATION;

EID: 77952124305     PISSN: 02710749     EISSN: None     Source Type: Journal    
DOI: 10.1097/JCP.0b013e3181d236ec     Document Type: Article

References (17)

1. Robertson MM. The prevalence and epidemiology of Gilles de la Tourette syndrome. Part 1 : the epidemiological and prevalence studies. J Psychosom Res. 2008; 65: 461-472.
2. Coffey BJ, Biederman J, Geller D, et al. Reexamining tic persistence and tic-associated impairment in Tourette's disorder: findings from a naturalistic follow-up study. J Nerv Ment Dis. 2004; 192: 776-780.
3. Freeman RD. Tic disorders and ADHD: answers from a world-wide clinical dataset on Tourette syndrome. Eur Child Adolesc Psychiatry. 2007; 16 (suppl 1): 15-23.
4. 4. Roessner V, Becker A, Banaschewski T, et al. Psychopathological profile in children with chronic tic disorder and co-existing ADHD: additive effects. J Abnorm Child Psychol. 2007; 35: 79-85. (Pubitemid 46399162)
5. 5. Roessner V, Robatzek M, Knapp G, et al. First-onset tics in patients with attention-deficit-hyperactivity disorder: impact of stimulants. Dev Med Child Neurol. 2006; 48: 616-621. (Pubitemid 43919072)
6. Bloch MH, Panza KE, Landeros-Weisenberger A, et al. Meta-analysis: treatment of attention-dcficit/hyperactivity disorder in children with comorbid tic disorders. J Am Acad Child Adolesc Psychiatry. 2009; 48: 884-893.
7. Muller-Vahl KR, Schneider U, Prevedel H, et al. Delta 9-tetrahydrocannabinol (THC) is effective in the treatment of tics in Tourette syndrome: a 6-week randomized trial. J Clin Psychiatry. 2003; 64: 459-465.
8. Moll GH, Heinrich H, Trott GE, et al. Children with comorbid attention-deficit-hyperactivity disorder and tic disorder: evidence for additive inhibitory deficits within the motor system. Ann Neurol. 2001; 49: 393-396.
9. Leckman JF, Riddle MA, Hardin MT, et al. The Yale Global Tic Severity Scale: initial testing of a clinician-rated scale of tic severity. J Am Acad Child Adolesc Psychiatry. 1989; 28: 566-573.
10. Cavanna AE, Schrag A, Morley D, et al. The Gilles de la Tourette syndrome-quality of life scale (GTS-QOL): development and validation. Neurology. 2008; 71: 1410-1416.
11. Conners CK. Conners' Teacher Rating Scales Revised. North Tonawanda, NY: Multi-Health Systems, Inc; 1997.
12. 12. Kujirai T, Caramia MD, Rothwell JC, et al. Corticocortical inhibition in human motor cortex. J Physiol. 1993; 471: 501-519. (Pubitemid 23345592)
13. 13. Valls-Sole J, Pascual-Leone A, Wassermann EM, et al. Human motor evoked responses to paired transcranial magnetic stimuli. Electroencephalogr Clin Neurophysiol. 1992; 85: 355-364. (Pubitemid 23011246)
14. 14. Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schkophr Bull. 1987; 13: 261-276. (Pubitemid 18039085)
15. Ziemann U. TMS and drugs. Clin Neurophysiol. 2004; 115: 1717-1729.
16. Iversen L. Cannabis and the brain. Brain. 2003; 126: 1252-1270.
17. 17. Sim-Selley LJ. Regulation of cannabinoid CB1 receptors in the central nervous system by chronic cannabinoids. Crit Rev Neurobiol. 2003; 15: 91-119. (Pubitemid 38160440)